International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer

van Leeuwen, Marieke; Kieffer, Jacobien M.; Efficace, Fabio; Fosså, Sophie D.; Bolla, Michel; Collette, Laurence; Colombel, Marc; De Giorgi, Ugo; Holzner, Bernhard; van de Poll-Franse, Lonneke V.; van Poppel, Hendrik; White, Jeff; de Wit, Ronald; Osanto, Susanne; Aaronson, Neil K.

doi:10.1186/s12955-017-0670-4

Table 3 Known group validity testing: Effect sizes for the differences within the prostate cancer sample between subgroups formed on the basis of comorbidity status, age, education and marital status

From: International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer

	PCa survivors
	Co-morbidities		Age			Education			Marital status
	0–1 comorbidities^a	2 or more co-morbidities	Younger than 70^a	70–80	80 and older	University^a	College and high school	Primary school only	Single^a	Partner
SF36: Physical Functioning		−0.60		−0.72	−1.05		−0.39	−0.67		0.22
SF36: Role-Physical		−0.66		−0.66	−0.84		−0.43	−0.44		−0.07
SF36: Bodily Pain		−0.86		−0.32	−0.55		−0.50	−0.53		−0.03
SF36: General Health		−0.48		−0.42	−0.73		−0.42	−0.70		0.30
SF36: Vitality		−0.57		−0.40	−0.58		−0.54	−0.73		0.03
SF36: Social Functioning		−0.47		−0.30	−0.41		−0.38	−0.56		0.27
SF36: Role-Emotional		−0.44		−0.46	−0.61		−0.56	−0.58		0.25
SF36: Mental Health		−0.49		−0.29	−0.65		−0.47	−1.02		0.26
QLQ-C30: Global health status/QoL		−0.61		−0.51	−0.85		−0.51	−0.79		−0.01
QLQ-C30: Physical Function		−0.58		−0.68	−0.95		−0.34	−0.63		0.12
QLQ-C30: Role Function		−0.52		−0.50	−0.55		−0.31	−0.59		−0.05
QLQ-C30: Emotional Function		−0.51		−0.27	−0.35		−0.35	−1.01		0.27
QLQ-C30: Cognitive Function		−0.49		−0.41	−0.87		−0.30	−0.48		0.03
QLQ-C30: Social Function		−0.58		−0.15	−0.29		−0.19	−0.53		0.37
QLQ-C30: Fatigue		−0.57		−0.23	−0.25		−0.53	−0.86		0.02
QLQ-C30: Nausea / vomiting		−0.14		0.07	−0.27		−0.10	−0.55		0.21
QLQ-C30: Pain		−0.58		−0.34	−0.40		−0.32	−0.27		−0.08
QLQ-C30: Dyspnoea		−0.54		−0.30	−0.60		−0.16	−0.65		0.34
QLQ-C30: Insomnia		−0.34		−0.39	−0.43		−0.32	−0.50		0.20
QLQ-C30: Appetite loss		−0.05		−0.23	0.29		−0.14	−0.63		0.09
QLQ-C30: Constipation		−0.50		−0.03	−0.57		−0.05	−0.66		0.04
QLQ-C30: Diarrhoea		−0.23		0.32	0.75		−0.07	0.16		0.32
QLQ-C30: Financial problems		0.12		0.63	0.35		−0.16	−0.21		0.36
IOC: Appearance concerns		−0.46		−0.38	−0.18		−0.25	−0.94		0.35
IOC: Body change concerns		−0.55		−0.41	−0.18		−0.42	−0.55		0.09
IOC: Life interferences		−0.59		−0.16	−0.28		−0.54	−0.84		0.16
IOC: Worry		−0.46		0.03	0.05		−0.05	−0.41		0.19
IOC: Negative Impact Scale		−0.62		−0.19	−0.15		−0.35	−0.73		0.21
PR25: Sexual activity		−0.12		−0.32	−0.75		0.05	−0.18		0.38
PR25: Sexual functioning		−0.51		−0.63	−0.35		0.25	0.22		0.23
PR25: Urinary problems		−0.50		−0.37	−0.60		−0.47	−0.67		0.27
PR25: Incontinence aid problems		−0.36		−0.74	−0.27		−0.43	−0.71		−0.30
PR25: Bowel problems		−0.39		−0.30	−0.51		−0.02	−0.61		0.16
PR25: Treatment related symptoms		−0.34		−0.27	−0.51		−0.54	−0.44		−0.01

Effect sizes are displayed in bold in those cases where the known groups differed significantly (p ≤ .05). A positive effect size reflects better HRQoL than the reference group, and a negative effect size reflects worse HRQoL than the reference group. ^areference group. PCa = prostate cancer

Back to article page

ISSN: 1477-7525

Contact us

Submission enquiries: journalsubmissions@springernature.com

Health and Quality of Life Outcomes

Contact us